---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-067589"
form_type: "8-K/A"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:06:44.812595+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Iovance files audited financials for Proleukin acquisition; FY2022 revenue $21.6M, net loss $10.2M

## Summary
- Proleukin revenue fell to $21.6M in FY2022 from $40.1M in FY2021; net loss of $10.2M vs profit $7.4M.
- Impairment of intangible assets of $2.7M recorded in FY2022.
- Auditors include going concern material uncertainty due to disposal to Iovance.
- Unaudited pro forma financials for Q1 2023 and FY2022 filed as Exhibit 99.3.

## SEC filing metadata
- accession: 0001104659-23-067589
- form_type: 8-K/A
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923067589/0001104659-23-067589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923067589/tm2317343d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-067589
- JSON: https://secwatch.observer/filing/0001104659-23-067589.json
- Plain text: https://secwatch.observer/filing/0001104659-23-067589.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.